Graft vs Host Disease (GVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Graft vs Host Disease (GVHD) is a condition in transplant rejection where the immune cells from the donor launch an immune attack against the recipient's tissues, perceiving them as foreign. This immune reaction primarily involves the donor's T cells (the graft) targeting and damaging the recipient's healthy cells (the host). GVHD has traditionally been categorized based on the onset time, with a cutoff point of 100 days following the transplant. The National Institutes of Health (NIH) has further classified GVHD based on recognized clinical manifestations into the following subtypes:

1.       Acute classic GVHD: This form appears within the first 100 days after transplantation and displays the typical clinical features of acute GVHD.

2.       Persistent, recurrent, or late-onset acute GVHD: This variation presents with the classic features of acute GVHD but occurs more than 100 days after the transplant.

3.       Classic chronic GVHD: Manifesting after the 100-day mark post-transplant, this type exhibits the characteristic clinical features of chronic GVHD.

4.       Overlap syndrome: This syndrome can emerge any time following the transplant and combines features of acute and chronic GVHD.

GVHD can develop under various circumstances, including after allogeneic bone transplantation (most commonly), after the transplantation of solid organs rich in lymphoid cells (e.g., liver), and following the transfusion of non-irradiated blood. GVHD's occurrence requires the transplantation of immunologically competent cells into immunodeficient recipients, and these transferred cells must recognize alloantigens within the recipient's body. Several crucial factors influence the occurrence and severity of GVHD, including donor-host factors, stem-cell source factors, immune modulation factors, and the use of chemotherapy and radiation therapy. The standard initial systemic treatment for acute GVHD typically involves corticosteroids, usually administered at a dose of 1-2 mg/kg/day of prednisone or its equivalent. However, around 50% of patients do not respond to steroids or become refractory to them (SR), leading to a poor long-term prognosis, with an estimated 40% nonrelapse mortality (NRM) rate within 12 months. Since 2017, the US Food and Drug Administration (FDA) has approved four treatments for GVHD: ruxolitinib (for both acute and chronic GVHD), ibrutinib (for chronic GVHD), and belumosudil (for chronic GVHD).

 

Thelansis’s “Graft vs Host Disease (GVHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Graft vs Host Disease (GVHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Graft vs Host Disease (GVHD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Graft vs Host Disease (GVHD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Graft vs Host Disease (GVHD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Graft vs Host Disease (GVHD), Graft vs Host Disease (GVHD) market outlook, Graft vs Host Disease (GVHD) competitive landscape, Graft vs Host Disease (GVHD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)